ASH Conference Coverage

Results from More Than 100 Abstracts Highlighting Celgene Pipeline Compounds and Therapies to Be Presented at the American Society of Hematology Annual Meeting (ASH)

(San Francisco Business Times) Nov 1, 2018 - First data read-out of pivotal Phase 3 MEDALIST trial in patients with myelodysplastic syndrome (MDS) to be highlighted during the ASH Plenary Session.

read article

Study: Denosumab Effective in Treating Osteoporosis in Transfusion Dependent Thalassemia

(ASH) Oct 31, 2018 - A new study published online today in the journal Blood Advances suggests that denosumab may improve spinal bone mineral density for patients with osteoporosis caused by transfusion-dependent thalassemia.

read press release

Multiple Abstracts Highlighting Data from Incyte’s Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting

(MarketWatch) Nov 1, 2018 - Results of REACH1 trial evaluating ruxolitinib (Jakafi®) in patients with steroid-refractory acute graft-versus-host disease (GVHD) accepted as an oral presentation.

read article

Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018

(AFP.com) Nov 1, 2018 - Gilead Sciences, Inc. today announced data from its oncology and cell therapy research programs will be presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, in San Diego from December 1 – 4, 2018. Twelve abstracts will be presented, including data highlighting Gilead’s broad cell therapy pipeline in hematologic malignancies and solid tumors.

read article

Celgene Keys In On ASH For Critical Look At Its Drugs Of The Future

(BioPharmaDive.com) Oct 25, 2018 - For December's ASH conference, Celgene execs said the following clinical trials will roll results out:

read article

New Southampton Study Could Help Tailor Treatment For Most Common Type Of Leukaemia

(University of Southampton [UK]) Dec 19, 2017 - New findings by scientists at the University of Southampton could help to predict how people with the most common form of leukaemia will respond to chemotherapy. The findings will help doctors decide which type of treatment to give patients.

read article

BioSight Announces Phase I/II Results of its Cytarabine Pro-Drug BST-236 for Treatment of Acute Leukemia

(Morningstar) Dec 14, 2017 - BioSight Ltd, a pharmaceutical development company, focused on the development of targeted oncology drugs, reports positive final results in a Phase I/II multi-center, open label, dose-escalating study of its lead product BST-236, a novel cytarabine pro-drug, as a single agent for induction therapy in acute leukemia patients.

read article

ASH 2017 – Transcend Fails To Prevent Juno’s Second Collapse

(EP Vantage) Dec 12, 2017 - Juno had hoped that the Ash meeting would mark its return as a competitive force in CAR-T. Instead, a keenly awaited update of its now pivotal lymphoma trial, Transcend, disappointed, and yesterday’s 14% share price collapse marked the second year in a row that Ash left the company nursing heavy losses.

read article

Advances in Multiple Myeloma, Lymphoma, and Histiocytosis among Results Presented at 2017 ASH Meeting

(MSK/OnCancer Blog) Dec 12, 2017 - At the 2017 meeting, held December 9 to 12 in Atlanta, Memorial Sloan Kettering researchers reported important progress in the treatment of several blood cancers.

read article

Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials

(Markets Insider) Dec 12, 2017 - Servier, Pfizer Inc. and Cellectis presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta preliminary results from two phase 1 studies of UCART19, an investigational allogeneic anti-CD19 CAR T-cell product, in adult and pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). These first-in-human data demonstrated the safety and tolerability of UCART19, resulting in an 83% complete remission rate across the adult and pediatric patient population.

read article

Study Shows Survival Benefits For Seeing An NCI Specialist For Multiple Myeloma

(UNC Lineberger) Dec 12, 2017 - Patients with multiple myeloma who saw a specialist at a National Cancer Institute-designated comprehensive Cancer Center had better overall survival than patients who only saw a community oncologist, according to a study from the University of North Carolina Lineberger Comprehensive Cancer Center.

read article

Interdisciplinary Teams Can Help Decrease Hospital Readmissions

(CureToday.com) Dec 13, 2017 - Hospital readmissions soon after discharge can be costly and detrimental to patient care, but according to a recent study conducted at the Cleveland Clinic and presented at the 2017 American Society of Hematology’s Annual Meeting and Exposition, creating an interdisciplinary team to work with patients can help.

read article

Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH

(Markets Insider) Dec 12, 2017 - Juno Therapeutics, Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today highlighted presentations and data from the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia, December 9-12, 2017.

read article

Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)

(Yahoo! Finance) Dec 13, 2017 - Spectrum Pharmaceuticals announced two oral presentations of data on FOLOTYN and research progress for the treatment of Peripheral T-Cell Lymphoma (PTCL) at the 59th American Society of Hematology (ASH).

read article

Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented

(NASDAQ) Dec 13, 2017 - Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, presented detailed data from its SL-401 pivotal trial in BPDCN, as well as results from other ongoing trials in additional indications, at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held in Atlanta, GA.

read article

Celgene CEO: New Therapies For A Certain Type Of Cancer Boost Survival Rates 10-Fold

(CNBC) Dec 11, 2017 - A new approach to treating patients suffering from an aggressive form of blood cancer could increase survival rates 10-fold to 20 years, Celgene CEO Mark Alles told CNBC on Monday.

read article

GSK Hails Progress On Its Most Advanced Cancer Drug

(The Telegraph [UK]) Dec 12, 2017 - Britain's biggest drugmaker GSK has hailed progress on its most advanced cancer drug, as the FTSE 100 firm battles to claw back lost ground in one of the world's most competitive medicines markets.

read article

Life-Shortening Blood Disease Gets Rush of Gene-Based Research

(Bloomberg) Dec 12, 2017 - More than 50 years after the cause of sickle-cell disease was discovered, a dozen treatments for the painful and life-shortening inherited condition offer hope for long-overlooked patients.

read article

Immuno-Oncology Drug Development -- Too Much Of A Good Thing?

(Forbes) Dec 12, 2017 - The annual meeting of the American Society of Hematology (ASH), now wrapping up in Atlanta, has generated a lot of excitement about immuno-oncology treatments like Bluebird Bio and Celgene’s experimental CAR-T targeting multiple myeloma.

read article

ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More

(Xconomy National) Dec 11, 2017 - The annual American Society of Hematology meeting is nearly over. For now, we’ve chosen updates from three disease areas to highlight, plus the more notable market movements.

read article
Next Page